Global Human Insulin Market Research Report - forecast to 2027

Global Human Insulin Market Research Report - forecast to 2027

ID: MRFR/HC/0350-CRR | June, 2015 | Region: Global | 110 pages | Cooked Research Reports

Global Human Insulin market Research Report by types (Traditional Human Insulin, Modern Human Insulin) By Regions (North America, Europe, Asia Pacific) - Forecast to 2027



Market Synopsis of Human Insulin Market
:


Market Scenario:
Human insulin refers to synthetic insulin manufactured in laboratories by growing insulin protein with the help of E. coli bacteria. Previously, before human insulin was established as animal insulin, usually a purified form of porcine (pork) insulin was used. It is expected that the market for global human insulin market is expected to grow at a CAGR of 12.1% from 2016 – 2027.


Key Players for Human Insulin Market:
Some of the key players for this market are: Biocon Ltd, Tonghua Dongbao Pharmaceuticals Co., Ltd., ADOCIA, Merck & Co, Julphar, Pfizer, Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Oramed Pharmaceuticals, Inc, Novo Nordisk A/S and Sanofi

Key Findings:


- Increasing prevalence of diabetic population, rising prevalence of obesity, and rise in geriatric population are major factors driving the growth of the human insulin market
 - Strict regulatory requirements for approval of insulin and high cost of insulin analog inhibits the growth of the human insulin market

Study Objectives of Human Insulin Market:



  • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Global Human Insulin Market

  • To provide insights about factors affecting the market growth

  • To Analyze the Global Human Insulin Market based on various factorsprice analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countriesNorth America, Europe, Asia, and

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by type, by region and sub-segments.

  • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Human Insulin Market



Segments:
Segmentation for the global human insulin market comprises of the following types such as


- Traditional Human Insulin which comprises of Short Acting Human Insulin, Intermediate Acting Human Insulin, and Premixed Human Insulin.
- Modern Human Insulin which consists of Long Acting Human Insulin, Rapid Acting Human Insulin and Premixed Human Insulin

 
Regional Analysis of Human Insulin Market:
North America is a prominent market for human insulin market and dominated the Global market share. It has been valued at $11,127.9 in 2015 million and is expected to grow over $XX million by 2027. The European human insulin market stands as second largest market which is expected to grow with a CAGR of 12.2% during the forecasted period. Asia Pacific has emerged as the fastest growing market which has been valued at US $6,298 million in 2015 and expected to reach US $XX million by the end of forecasted period with the CAGR of more than 13.2%.


Americas



  • North America

  • US

  • Canada

  • Latin America


Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • U.K

  • Rest of Western Europe

  • Eastern Europe


Asia– Pacific



  • Asia

  • China

  • India

  • Japan

  • South Korea

  • Rest of Asia


Pacific


The Middle East & Africa


The report for Global Human insulin Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
TABLE OF CONTENTS

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.2.1 RESEARCH OBJECTIVE
2.2.2 ASSUMPTIONS
2.2.3 LIMITATIONS
2.3 MARKET STRUCTURE
2.4. MARKET SEGMENTATION

3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
3.5 FORECAST MODEL

4.1 DRIVERS
4.2 RESTRAINTS
4.3 OPPORTUNITIES
4.4 MEGA TRENDS
4.5 MACROECONOMIC INDICATORS
4.6 IMPORTANT POINTERS BY INDUSTRY EXPERTS
4.6.1 FASTEST GROWING MARKET
4.6.2 GROWTH PROSPECTS
4.7 REGULATIONS/ACTS

5.1 VALUE CHAIN ANALYSIS
5.2 PORTERS

6.1 INTRODUCTION
6.2 HISTORIC MARKET GROWTH
6.3 MARKET SIZE (SUB SEGMENTS)
6.3.1 Traditional Human Insulin
6.3.2 Modern Human Insulin

7.1 INTRODUCTION
7.2 MARKET SIZE BY REGION
7.2.1 AMERICAS
7.2.1.1 NORTH AMERICA
7.2.1.1.1 US
7.2.1.1.2 CANADA
7.2.1.2 LATIN AMERICA
7.2.2 EUROPE
7.2.2.1 WESTERN EUROPE
7.2.2.1.1 GERMANY
7.2.2.1.2 FRANCE
7.2.2.1.2 Italy
7.2.2.1.4 Spain
7.2.2.1.5 UK
7.2.2.1.6 REST OF WESTERN EUROPE
7.2.3.1 EASTERN EUROPE
7.2.3 ASIA-PACIFIC
7.2.3.1 CHINA
7.2.3.2 INDIA
7.2.3.3 JAPAN
7.2.3.4 REST OF ASIA PACIFIC
7.2.4 MIDDLE EAST & AFRICA

8.1 INTRODUCTION
8.2 PRODUCT LAUNCH/DEVELOPMENT
8.3 PARTNERSHIPS AND COLLABORATIONS
8.4 ACQUISITIONS
8.5 BUSINESS EXPANSION

9.1 Biocon Ltd
9.1.1 COMPANY OVERVIEW
9.1.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.1.3 FINANCIAL UPDATES
9.1.4 KEY DEVELOPMENTS
9.2 Tonghua Dongbao Pharmaceuticals Co
9.2.1 COMPANY OVERVIEW
9.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.2.3 FINANCIAL UPDATES
9.2.4 KEY DEVELOPMENTS
9.3 ADOCIA, Merck & Co
9.3.1 COMPANY OVERVIEW
9.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.3.3 FINANCIAL UPDATES
9.3.4 KEY DEVELOPMENTS
9.4 Julphar
9.4.1 COMPANY OVERVIEW
9.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.4.3 FINANCIAL UPDATES
9.4.4 KEY DEVELOPMENTS
9.5 Pfizer
9.5.1 COMPANY OVERVIEW
9.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.5.3 FINANCIAL UPDATES
9.5.4 KEY DEVELOPMENTS
9.6 Bristol-Myers Squibb Company
9.6.1 COMPANY OVERVIEW
9.6.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.6.3 FINANCIAL UPDATES
9.6.4 KEY DEVELOPMENTS
9.7 GlaxoSmithKline
9.7.1 COMPANY OVERVIEW
9.7.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.7.3 FINANCIAL UPDATES
9.7.4 KEY DEVELOPMENTS
9.8 Oramed Pharmaceuticals
9.8.1 COMPANY OVERVIEW
9.8.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.8.3 FINANCIAL UPDATES
9.8.4 KEY DEVELOPMENTS
9.9 Novo Nordisk A/S
9.9.1 COMPANY OVERVIEW
9.9.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.9.3 FINANCIAL UPDATES
9.9.4 KEY DEVELOPMENTS
9.1 Sanofi
9.10.1 COMPANY OVERVIEW
9.10.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
9.10.3 FINANCIAL UPDATES
9.10.4 KEY DEVELOPMENTS